CopyMark Law Group
4.9/5
Drawing for KISIMA

USPTO serial 87149001

KISIMA

Reviewed by CopyMark Law Group

Reg. 5577986Status 710
Filing date
Status date
Registration date
Oct 9, 2018
Examiner
IM, JEAN H
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with KISIMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jennifer Fraser

JENNIFER FRASER DYKEMA GOSSETT PLLC1301 K STREET, NWSUITE 1100 WESTWASHINGTON, DC 20005

Goods and services

ClassDescriptionStatusFirst use
001Peptides, proteins, modified peptides and proteins and derivatives of peptides and proteins used in industry and science, in particular peptides, proteins, modified peptides and proteins and derivatives of peptides and proteins for industrial and scientific purposes, all the foregoing being chemical preparations for industrial and scientific use; biochemical products, in the nature of biochemical preparations and substances for analyses in laboratories; diagnostic preparations containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific purposes; peptide substrates for scientific purposes, namely, biochemical peptide substrates for laboratory or research use; proteins for use in science, industry and manufacture; biological preparations, namely, cell cultures, tissue cultures; chemical reagents containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific and research purposes and biochemical reagents containing peptides, proteins, modified peptides, modified proteins, derivatives of peptides, derivatives of proteins, nucleic acids, derivatives of nucleic acids, or cells for scientific and research purposes; nucleic acids, in particular recombinant nucleic acids; nucleic acids for scientific purposes; nucleic acid sequences; biological active peptides for scientific and research purposes; antisera for scientific and industrial purposes; all above other than for medical and veterinary useSECTION 8 - CANCELLED—
005Pharmaceutical, medical and veterinary preparations, namely, proteins, peptides, and modified peptides for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; proteins and derivatives of peptides and proteins as well as protein- and peptide-pools for medical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; macromolecules, namely, peptides, proteins, nucleic acids and derivatives of peptides, proteins, and nucleic acids for medical and pharmaceutical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; diagnostic preparations for medical and veterinary use; biological preparations, namely, proteins, peptides, modified peptides for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; cells for medical purposes; pharmaceutical preparations and compositions, namely, pharmaceutical preparations and compositions for the treatment and prevention of cancer; nucleic acids, in particular recombinant nucleic acids; nucleic acids for medical purposes, namely, for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; nucleic acid sequences for medical purposes, namely, for diagnostic purposes and the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; proteins for medical purposes, namely, for diagnostic purposes and for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; macromolecules and biologically active substances for medical purposes for the treatment and prevention of tumor and cancer diseases, infectious diseases, and autoimmune diseases; kits containing preparations for medical purposes, comprised primarily of pharmaceutical preparations for the treatment and prevention of tumor and cancer diseases, and pharmaceutical preparations namely, proteins, peptides, modified peptides for the treatment and prevention of infectious diseases, and autoimmune diseasesSECTION 8 - CANCELLED—
042Scientific and technological services and research and design relating thereto, namely, scientific research, analysis and testing in the field of pharmaceuticals, medicine, biochemistry and biotechnology, and design of biochemical macromolecules, in particular proteins, peptides and nucleic acids, and biochemical preparations for scientific, medical and industrial use; Industrial analysis and research services in the field of pharmaceuticals, medicine, biochemistry and biotechnology; research and development services all relating to science; medical product and pharmaceutical research and development services; biological scientific research and development and clinical scientific research and development services; research and development services all relating to industry in the field of pharmaceuticals, medicine, biochemistry and biotechnology; research and development services all relating to biochemistry and biotechnology; research and development services all relating to products and tools to be used in biotechnical, biochemical, medical and pharmaceutical research; medical and pharmacological research services; medical research; scientific research for medical purposes; laboratory research services in the field of protein, peptide and molecular biology; provision of information and data relating to medical product and scientific research and development; medical and pharmaceutical product development and evaluation; Pharmaceutical, medical, biotechnological and biochemical research and development services for the pharmaceutical industry; Information technology services for the pharmaceutical and healthcare industries, namely, planning, design and management of information technology systems, consulting in the field of information technology, design and development of computer softwareSECTION 8 - CANCELLED—
044Medical services; Veterinary services; Hygienic and beauty care for human beings or animals; Agriculture, horticulture and forestry services, namely, pest control for agriculture, horticulture and forestry, farming services in the field of grain; Pharmaceutical services, namely, pharmaceutical advice, pharmaceutical compounding services; Medical informationSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 25, 2025C8..CANCELLED SEC. 8 (6-YR)—
Oct 9, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Oct 9, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 24, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 24, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 4, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 20, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 18, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 18, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 11, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 11, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 20, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 20, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 28, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 28, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 26, 2017ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Jun 8, 2017GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Jun 8, 2017GNSLLETTER OF SUSPENSION E-MAILED—
Jun 8, 2017CNSLSUSPENSION LETTER WRITTEN—
May 16, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 16, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 12, 2017ALIEASSIGNED TO LIE—
Apr 20, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 7, 2016GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2016GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 7, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 5, 2016DOCKASSIGNED TO EXAMINER—
Aug 29, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 27, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance